ArticleJournal of nanobiotechnology2026
Engineered lipid hybrid nanoparticles for targeted delivery of SH2 superbinder and breast cancer therapy.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nanoceria-curcumin nanoplatform enhances radiotherapy efficacy in triple-negative breast cancer via microenvironmental redox modulation and TNF-α-NF-κB/inflammatory program suppression.Materials today. Bio · 2026Article
- cRGD-Targeted Nanoparticles Co-Loaded with Ag, Quercetin and PD-L1 siRNA with Combined Antibacterial and Immunotherapeutic Functions AgainstInternational journal of nanomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
SH2 Superbinder (SH2S) is an engineered polypeptide tool derived from the SH2 domain. It exhibits significantly enhanced binding capacity for tyrosine-phosphorylated proteins to treat various cancers. However, its clinical application is limited by poor serum stability and insufficient tumor targeting. To solve these problems, engineered SH2S-loaded Lipid Hybrid Nanoparticles (SLHN) was developed by using cationic polymer poly (β-amino ester), lipids and cholesterol via a modified microfluidic technology. SLHN efficiently delivers the SH2S into tumor cells via membrane fusion and clathrin-mediated endocytosis. Inside cells, it replaces natural proteins containing the SH2 domain, then inducing apoptosis and inhibiting growth in tumor cells by blocking the phosphorylation of AKT, ERK and STAT3. Furthermore, SLHN modified with cRGD peptide (SLHN-R) exhibits improved tumor targeting capabilities and and the ability to modulate the tumor microenvironment (promoting CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.